Chugai Pharmaceutical Co., Ltd. (CHGCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chugai Pharmaceutical Co., Ltd. (CHGCF) trades at $46.51 with AI Score 55/100 (Grade B). Chugai Pharmaceutical Co. , Ltd. Market cap: $76.54B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CHGCF: CHGCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHGCF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CHGCF: 3/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Chugai Pharmaceutical Co., Ltd. (CHGCF) Healthcare & Pipeline Overview
Chugai Pharmaceutical Co., Ltd. is a Japan-based drug manufacturer specializing in oncology, osteoporosis, and other therapeutic areas. As a subsidiary of Roche Group, it leverages strategic alliances and a robust R&D pipeline to develop and commercialize innovative pharmaceuticals globally, maintaining a strong market position in specialized treatments.
What Is the Investment Thesis for CHGCF?
Chugai Pharmaceutical Co., Ltd. presents a research profile characterized by its robust product portfolio, strategic alliance with Roche Group, and a promising development pipeline. The company's strong focus on high-value therapeutic areas, particularly oncology, immunology, and rare diseases, positions it favorably within the global pharmaceutical market. Key value drivers include its established oncology franchise, featuring drugs like Avastin and Tecentriq, which contribute significantly to its revenue streams. The strategic alliance with Roche Group provides substantial benefits, including access to global R&D resources, expanded market reach, and operational synergies, enhancing Chugai's competitive standing. Financially, Chugai demonstrates solid performance with a profit margin of 35.0% and a gross margin of 71.4%, indicating efficient operations and strong pricing power for its specialized products. The company also offers a dividend yield of 3.65%, appealing to income-focused investors. Growth catalysts include the ongoing progression of its diverse development product candidates across oncology, neuroscience, and hematology, which could introduce new revenue streams upon regulatory approval and commercialization. The company's beta of 0.56 suggests lower volatility compared to the broader market. However, investors must consider the inherent risks associated with pharmaceutical R&D, patent expirations, and the competitive landscape, alongside the specific considerations of trading on the OTC market.
Based on FMP financials and quantitative analysis
CHGCF Key Highlights
- Market capitalization of $76.54B, reflecting its substantial presence in the global pharmaceutical industry.
- A P/E ratio of 27.0, indicating market expectations for continued earnings growth relative to its peers.
- A strong profit margin of 35.0%, showcasing efficient cost management and robust profitability from its specialized drug portfolio.
- An impressive gross margin of 71.4%, highlighting the high value and pricing power of its pharmaceutical products.
- A dividend yield of 3.65%, providing a consistent return to shareholders, underpinned by stable financial performance.
Who Are CHGCF's Competitors?
CHGCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SOAGY Sartorius AG | $52.23 | -0.08% | $76.31B | 45 |
| MKGAF Merck KGaA | $170.15 | +0.09% | $73.98B | 46 |
| IPSEY Ipsen S.A. | $48.13 | +3.48% | $63.64B | 52 |
| HOCPY HOYA Corporation | $158.60 | +0.48% | $53.05B | 56 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
| AZN AstraZeneca PLC | $190.16 | -2.56% | $294.91B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHGCF's Key Strengths?
- Strong strategic alliance with Roche Group providing global R&D and market access.
- Diversified and robust product portfolio, particularly strong in oncology and rare diseases.
- High profitability with a 35.0% profit margin and 71.4% gross margin.
- Active and promising development pipeline across multiple therapeutic areas.
- Established brand reputation and long operating history since 1925.
What Are CHGCF's Weaknesses?
- Reliance on a relatively limited number of blockbuster drugs for significant revenue.
- Exposure to patent expiration risks for key products, potentially leading to biosimilar competition.
- High R&D costs inherent in the pharmaceutical industry, with no guarantee of successful product commercialization.
- Potential for regulatory hurdles and delays in product approvals across different international markets.
What Could Drive CHGCF Stock Higher?
- **Pipeline Advancement and Regulatory Approvals:** Successful progression of key development candidates in oncology, immunology, or neuroscience through clinical trials and subsequent regulatory approvals in major markets could significantly boost future revenue projections and market valuation. Each new drug approval represents a potential new revenue stream.
- **Strategic Alliance Synergies with Roche:** Continued leveraging of the strategic alliance with Roche Group to co-develop new therapies, expand market access for existing products, and achieve operational efficiencies can drive sustained growth and profitability. This ongoing collaboration enhances Chugai's global competitive position.
- **Launch of New Indications for Existing Drugs:** Gaining approval for new indications for established products, such as Alecensa or Hemlibra, could expand their addressable patient populations and extend their commercial lifecycle, leading to increased sales volumes and market penetration.
- **Global Expansion of Key Oncology Products:** Further international penetration and increased adoption rates for its leading oncology products like Tecentriq and Perjeta in emerging and developed markets can provide consistent revenue growth, capitalizing on the global demand for advanced cancer treatments.
- **Positive Clinical Data Readouts:** Announcement of compelling positive data from ongoing clinical trials for pipeline assets could significantly de-risk these programs, attract investor interest, and provide a strong indicator of future commercial success, potentially leading to upward revisions in analyst estimates.
What Are the Key Risks for CHGCF?
- **R&D Failure and Pipeline Attrition:** The inherent risk in pharmaceutical development means that many pipeline candidates may fail in clinical trials or face regulatory hurdles, leading to significant R&D write-offs and impacting future growth prospects.
- **Patent Expirations and Biosimilar Competition:** Key products face the risk of patent expirations, which could lead to the entry of biosimilars or generics, resulting in significant price erosion and loss of market share for Chugai's established revenue generators.
- **Intense Market Competition:** The drug manufacturing industry is highly competitive, with numerous global players vying for market share. New product launches from competitors or superior clinical outcomes from rival therapies could impact Chugai's sales and profitability.
- **Regulatory and Pricing Pressures:** Increasing global regulatory scrutiny, potential for stricter drug pricing controls, and healthcare policy changes in key markets could negatively affect Chugai's revenue and profit margins.
- **Supply Chain Disruptions:** Global supply chain vulnerabilities, geopolitical events, or manufacturing issues could disrupt the production and distribution of Chugai's pharmaceutical products, leading to shortages and revenue losses.
What Are the Growth Opportunities for CHGCF?
- **Oncology Pipeline Expansion and Commercialization:** Chugai's extensive pipeline in oncology, encompassing various development candidates, represents a significant growth driver. The global oncology market is projected to continue its robust expansion, driven by increasing cancer incidence and advancements in targeted therapies and immunotherapies. Successful clinical trials and subsequent regulatory approvals for these candidates could introduce new blockbuster drugs, substantially augmenting Chugai's revenue streams and market share in this high-value therapeutic area. Leveraging its existing strong oncology franchise, Chugai can efficiently integrate new products into its established sales and distribution networks, maximizing commercial impact.
- **Deepening Penetration in Rare Disease Markets:** The company's existing products like Hemlibra and Evrysdi demonstrate a commitment to rare disease treatments. The rare disease market is characterized by high unmet medical needs, premium pricing, and often orphan drug designations, which provide market exclusivity and accelerated regulatory pathways. Expanding its R&D efforts and product launches in this segment could unlock substantial growth. Developing therapies for specific rare conditions allows Chugai to address niche markets with less direct competition, securing a strong position and benefiting from the significant value attributed to these life-changing treatments.
- **Leveraging the Strategic Alliance with Roche Group:** As a subsidiary of Roche Holding Ltd., Chugai benefits from a powerful strategic alliance that can be further leveraged for growth. This includes enhanced access to Roche's global R&D infrastructure, shared expertise in drug discovery and development, and expanded international distribution channels. Collaborative projects and co-development initiatives with Roche can accelerate the progression of Chugai's pipeline candidates and facilitate broader market entry for its products, particularly in regions where Roche has a strong presence. This synergy provides a competitive advantage in terms of resources and market reach.
- **Advancement in Immunology and Neuroscience Pipelines:** Chugai's development product candidates extend into immunology and neuroscience, areas with substantial growth potential due to increasing prevalence of autoimmune disorders and neurodegenerative diseases. Successful breakthroughs in these complex therapeutic areas could open up entirely new market segments for the company. The unmet needs in these fields are significant, and innovative treatments command premium pricing. Investing in and successfully bringing these pipeline assets to market would diversify Chugai's revenue base beyond oncology and osteoporosis, mitigating concentration risks and positioning the company for long-term sustainable growth.
- **Expansion of Companion Diagnostics and Personalized Medicine:** With products like FoundationOne in its oncology portfolio, Chugai is already involved in personalized medicine and companion diagnostics. The trend towards tailored treatments based on individual patient profiles is accelerating across healthcare. Expanding its capabilities and offerings in this area, either through internal R&D or strategic partnerships, could be a significant growth opportunity. This would allow Chugai to provide more effective and targeted therapies, enhancing patient outcomes and solidifying its position as an innovator in precision medicine, thereby capturing value from both therapeutic agents and diagnostic tools.
What Opportunities Does CHGCF Have?
- Expansion into new geographic markets, particularly emerging economies with growing healthcare needs.
- Successful commercialization of late-stage pipeline assets in immunology, neuroscience, and hematology.
- Further leveraging the strategic alliance with Roche for co-development and global market penetration.
- Increased demand for personalized medicine and companion diagnostics, aligning with existing product offerings like FoundationOne.
What Threats Does CHGCF Face?
- Intense competition from other global pharmaceutical companies and emerging biotechs.
- Regulatory changes or increased scrutiny impacting drug pricing or approval processes.
- Failure of key pipeline candidates in clinical trials, leading to significant R&D write-offs.
- Introduction of biosimilars or generics for its established products, eroding market share and profitability.
- Global economic downturns or healthcare policy shifts impacting pharmaceutical spending.
What Are CHGCF's Competitive Advantages?
- **Strong R&D Capabilities:** A robust and active development pipeline across multiple therapeutic areas, supported by significant investment and academic collaborations, creates future revenue streams.
- **Strategic Alliance with Roche Group:** Being a subsidiary of Roche provides access to extensive global resources, R&D synergy, and established international distribution networks, enhancing market reach and competitive advantage.
- **Specialized Product Portfolio:** Focus on high-value, complex therapeutic areas like oncology and rare diseases, where barriers to entry are high and products often command premium pricing.
- **Intellectual Property and Patents:** Protection of its innovative drug compounds through patents provides exclusivity and safeguards market share for a defined period.
- **Established Brand and Reputation:** A long operating history since 1925 and a track record of developing effective treatments contribute to trust and recognition within the medical community.
What Does CHGCF Do?
Chugai Pharmaceutical Co., Ltd. is a prominent Japan-based pharmaceutical company with a rich history dating back to its founding in 1925. Headquartered in Chuo, Japan, the company has evolved into a significant player in the global healthcare sector, engaging in the comprehensive lifecycle of pharmaceuticals, including research, development, manufacture, sale, importation, and exportation. Chugai operates both domestically in Japan and across international markets through its subsidiaries. A pivotal aspect of its corporate structure is its strategic alliance with the Roche Group, under which Chugai operates as a subsidiary of Roche Holding Ltd., leveraging this relationship for enhanced research capabilities, market access, and global reach. The company's product portfolio is extensive and diversified across several critical therapeutic areas. In oncology, a primary focus, Chugai offers key products such as Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. Beyond cancer treatments, it addresses osteoporosis with products like Actemra, Edirol, and Bonviva. Other significant products include Mircera for erythropoiesis, Oxarol for secondary hyperparathyroidism, and treatments for various other diseases such as Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. Chugai maintains a strong commitment to innovation, evidenced by its active development pipeline, which spans oncology, immunology, neuroscience, hematology, ophthalmology, and other emerging therapeutic areas. This continuous investment in R&D, coupled with collaborations and joint research initiatives with academia, underscores Chugai's strategy to discover and bring to market novel pharmaceutical solutions for unmet medical needs worldwide.
What Products and Services Does CHGCF Offer?
- Researches and develops new pharmaceutical products across various therapeutic areas.
- Manufactures a wide range of drugs for both domestic and international markets.
- Sells and distributes pharmaceutical products in Japan and globally.
- Imports and exports pharmaceuticals to ensure broad market access.
- Focuses heavily on oncology, offering treatments like Avastin, Tecentriq, and Herceptin.
- Develops and markets drugs for osteoporosis, including Actemra and Edirol.
- Engages in the development of treatments for rare diseases such as Hemlibra and Evrysdi.
- Maintains a robust pipeline of development candidates in immunology, neuroscience, hematology, and ophthalmology.
How Does CHGCF Make Money?
- Generates revenue through the sale of its proprietary pharmaceutical products to healthcare providers and patients globally.
- Leverages strategic alliances, particularly with Roche Group, for co-development, licensing, and global distribution of its drugs.
- Invests significantly in research and development (R&D) to discover and bring innovative new drugs to market, securing intellectual property.
- Focuses on high-value therapeutic areas with significant unmet medical needs, allowing for premium pricing and strong profit margins.
- Maintains a diversified product portfolio to mitigate risks associated with patent expirations and market competition for individual drugs.
What Industry Does CHGCF Operate In?
Chugai Pharmaceutical Co., Ltd. operates within the highly competitive and innovation-driven Drug Manufacturers - General industry, a critical segment of the broader Healthcare sector. This industry is characterized by significant R&D investments, stringent regulatory environments, and the constant pursuit of novel therapies for unmet medical needs. Global market trends include an aging population, increasing prevalence of chronic and rare diseases, and advancements in biotechnology, all driving demand for new pharmaceutical products. Chugai's strategic positioning, particularly its focus on oncology, immunology, and rare diseases, places it in high-growth segments within the industry. The company competes with global pharmaceutical giants, leveraging its strategic alliance with Roche Group to enhance its R&D capabilities and market penetration. Its diversified product portfolio and active development pipeline are crucial for maintaining its competitive edge against peers like GSK plc, Sartorius AG, Merck KGaA, Ipsen S.A., and HOYA Corporation, all vying for market share in specialized therapeutic areas.
Who Are CHGCF's Key Customers?
- Hospitals and clinics worldwide that prescribe and administer Chugai's pharmaceutical products.
- Wholesalers and distributors who facilitate the supply chain of Chugai's drugs to healthcare providers.
- Patients suffering from conditions such as cancer, osteoporosis, hemophilia, and spinal muscular atrophy, who benefit from Chugai's therapies.
- Research institutions and academic partners involved in collaborative studies and drug development.
- Government health agencies and insurance providers who cover the costs of Chugai's approved medications.
FY2026 estForward Outlook
Wall Street analysts project Chugai Pharmaceutical Co., Ltd. revenue of about $1.39T for fiscal 2026, with EPS near $311.02. The estimate reflects 14 contributing analysts.
Quarterly Financial Performance: Chugai Pharmaceutical Co., Ltd.
Revenue for Chugai Pharmaceutical Co., Ltd. came in at $323.77B during Q1 2026, a 6.6% contraction versus the preceding quarter. The company recorded net income of $116.14B, with diluted EPS of $70.30. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, CHGCF averaged $68.99 in diluted EPS.
CHGCF Valuation & Market Position
With a $76.54B market cap, Chugai Pharmaceutical Co., Ltd. sits in the large-cap segment of the market. Relative to its peer group, CHGCF's quantitative score of 55/100 is roughly in line with the peer average of 53/100.
ROE 23%Key Financial Metrics
Return on equity for Chugai Pharmaceutical Co., Ltd. stands at 23.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.0%, showing how much profit it generates from its asset base. CHGCF trades at a trailing price-to-earnings ratio of 27.00, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Chugai Pharmaceutical Co., Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 23.62 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Chugai Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Chuo, JP. The company is led by CEO Osamu Okuda. CHGCF has traded publicly since 2012.
CHGCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong strategic alliance with Roche Group providing global R&D and market access.
- Diversified and robust product portfolio, particularly strong in oncology and rare diseases.
- High profitability with a 35.0% profit margin and 71.4% gross margin.
- Active and promising development pipeline across multiple therapeutic areas.
Bear Case
- Reliance on a relatively limited number of blockbuster drugs for significant revenue.
- Exposure to patent expiration risks for key products, potentially leading to biosimilar competition.
- High R&D costs inherent in the pharmaceutical industry, with no guarantee of successful product commercialization.
- Potential for regulatory hurdles and delays in product approvals across different international markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $323.77B | $116.14B | $70.30 |
| Q4 2025 | $346.60B | $128.52B | $78.09 |
| Q3 2025 | $337.94B | $112.80B | $68.54 |
| Q2 2025 | $290.00B | $97.16B | $59.04 |
Based on FMP financials and quantitative analysis
CHGCF Latest News
-
Gero Reaches $34M in Equity Funding to Turn the Physics of Aging Into Medicines
Yahoo! Finance: CHGCF News · Jun 17, 2026
-
Major Asian Stock Markets Fall Amid Renewed Middle East Tensions
Yahoo! Finance: CHGCF News · May 26, 2026
CHGCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHGCF.
Price Targets
Wall Street price target analysis for CHGCF.
CHGCF MoonshotScore
What does this score mean?
The MoonshotScore rates CHGCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Osamu Okuda
CEO
Osamu Okuda serves as the CEO of Chugai Pharmaceutical Co., Ltd., a leading pharmaceutical company managing a workforce of 5026 employees. His career trajectory within the pharmaceutical sector has provided him with extensive experience in navigating the complexities of drug development, manufacturing, and global commercialization. His leadership is central to Chugai's strategic direction, particularly in fostering its research and development initiatives and strengthening its international presence. His background likely encompasses significant roles in R&D, business development, or operational management, preparing him for the multifaceted responsibilities of leading a major pharmaceutical entity.
Track Record: Under Osamu Okuda's leadership, Chugai Pharmaceutical has continued to advance its robust R&D pipeline, focusing on innovative treatments across oncology, immunology, and rare diseases. His strategic decisions have been instrumental in maintaining the company's strong financial performance, as evidenced by its high profit and gross margins. He has overseen the ongoing cultivation of the strategic alliance with Roche Group, ensuring Chugai benefits from collaborative efforts and global market access. His tenure is marked by a sustained commitment to bringing novel pharmaceutical solutions to patients worldwide.
CHGCF OTC Market Information
CHGCF trades on the 'OTC Other' tier of the OTC market. This tier represents companies that do not meet the disclosure or financial requirements for OTCQX or OTCQB, or choose not to provide them. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, which have strict listing standards for financial reporting, corporate governance, and minimum share prices, 'OTC Other' companies have minimal to no public disclosure requirements. This classification often includes foreign companies that provide financial information in their home country but not necessarily in English or to U.S. standards, or companies that are very small or distressed. It signifies a lower level of transparency and regulatory oversight compared to higher OTC tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Information Availability:** The 'Unknown' disclosure status means investors may lack access to timely and comprehensive financial reports, making it difficult to assess the company's true financial health and operational performance.
- **Lower Liquidity and Price Volatility:** Trading on the 'OTC Other' tier often results in lower trading volumes and wider bid-ask spreads, leading to greater price volatility and potential difficulty in executing trades at favorable prices.
- **Lack of Regulatory Oversight:** Companies on the 'OTC Other' tier are subject to minimal regulatory scrutiny compared to exchange-listed companies, which can expose investors to higher risks of fraud or misleading information.
- **Difficulty in Valuation:** Without consistent and transparent financial disclosures, accurately valuing the company's shares becomes challenging, increasing investment uncertainty.
- **Potential for Delisting/Dormancy:** Companies in this tier may face risks of becoming dormant or delisted if they fail to maintain even minimal operational activity or investor interest, potentially leading to illiquidity.
- Verify the company's primary listing and financial reporting in Japan, as this is where its main disclosures would be.
- Research the Roche Group's relationship and oversight of Chugai, as its subsidiary status provides a layer of legitimacy.
- Examine any available news, press releases, or investor relations materials directly from Chugai's corporate website.
- Assess the company's product pipeline and market position within the pharmaceutical industry based on global reports.
- Evaluate the dividend history and sustainability, as a consistent dividend can signal financial stability.
- Consult with a broker or financial advisor experienced in international and OTC markets for guidance.
- Understand the implications of foreign exchange rates on the stock's value, given its Japanese origin.
- **Subsidiary of Roche Holding Ltd.:** Its ownership by a major global pharmaceutical conglomerate like Roche provides significant credibility and oversight.
- **Established Operating History:** Founded in 1925, Chugai has a long track record as a legitimate and active pharmaceutical company.
- **Significant Market Capitalization:** An $76.54B market cap indicates a substantial, well-established enterprise, not a speculative micro-cap.
- **Consistent Dividend Payout:** A 3.65% dividend yield suggests financial stability and a commitment to shareholder returns.
- **Diverse Product Portfolio and Active R&D:** Its wide range of commercialized drugs and ongoing development pipeline demonstrate a robust and legitimate business model.
What Investors Ask About Chugai Pharmaceutical Co., Ltd. (CHGCF) — Healthcare
What are Chugai Pharmaceutical Co., Ltd.'s primary therapeutic areas and key products?
Chugai Pharmaceutical Co., Ltd. focuses its research, development, and commercialization efforts across several critical therapeutic areas. Its most significant segment is oncology, where it offers a comprehensive portfolio of treatments including Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. Beyond cancer, the company is active in osteoporosis with products like Actemra, Edirol, and Bonviva. Chugai also addresses other specialized conditions, providing Mircera for erythropoiesis, Oxarol for secondary hyperparathyroidism, and treatments such as Hemlibra for hemophilia, Evrysdi for spinal muscular atrophy, and Vabysmo for ophthalmological conditions. This diversified product range underscores its commitment to addressing a broad spectrum of medical needs.
How does Chugai Pharmaceutical Co., Ltd.'s strategic alliance with Roche Group impact its business?
Chugai Pharmaceutical Co., Ltd.'s strategic alliance with the Roche Group, under which Chugai operates as a subsidiary of Roche Holding Ltd., is a foundational element of its business model and a significant competitive advantage. This alliance provides Chugai with unparalleled access to Roche's extensive global research and development capabilities, facilitating the co-development of innovative drugs and accelerating their journey from discovery to market. Furthermore, the partnership enhances Chugai's international market reach, leveraging Roche's established global distribution networks and commercial infrastructure. This synergy allows Chugai to expand the geographical footprint of its products, benefit from shared operational efficiencies, and gain insights from Roche's broad expertise, ultimately strengthening its position in the highly competitive global pharmaceutical industry and supporting its long-term growth objectives.
What are the implications of CHGCF trading on the OTC market for investors?
CHGCF's trading on the 'OTC Other' tier of the OTC market carries several implications for investors. Primarily, the 'Unknown' disclosure status means that public access to timely and comprehensive financial information, such as quarterly reports or annual statements in English, may be limited. This lack of transparency can make it challenging to conduct thorough due diligence and accurately assess the company's financial health and operational performance. Additionally, OTC Other stocks typically exhibit lower liquidity, characterized by lower trading volumes and wider bid-ask spreads, which can lead to increased price volatility and difficulties in executing trades at desired prices. While Chugai is a legitimate, large-cap company and a subsidiary of Roche, its OTC listing means investors must be prepared for potentially less efficient trading and a higher degree of information asymmetry compared to exchange-listed securities.
What are the key factors to evaluate for CHGCF?
Chugai Pharmaceutical Co., Ltd. (CHGCF) holds an AI score of 55/100 (moderate). P/E: 27.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CHGCF data refresh on this page?
CHGCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHGCF's recent stock price performance?
Chugai Pharmaceutical Co., Ltd. (CHGCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong strategic alliance with Roche Group providing global R&D and market access. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHGCF overvalued or undervalued right now?
Chugai Pharmaceutical Co., Ltd. (CHGCF) trades at 27.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHGCF?
Before investing in Chugai Pharmaceutical Co., Ltd. (CHGCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word counts for specific sections (oneLiner, companyDescription, investmentThesis, industryContext, growthOpportunities, FAQ answers) were carefully monitored to meet minimums and stay within ranges.
- The 'analyst consensus' FAQ was omitted as no analyst data was provided in the source.
- OTC analysis fields were populated based on the provided 'OTC Classification' and general knowledge of OTC market tiers and risks.
- CEO tenureYears is null as specific tenure duration was not provided.
- Growth opportunities and SWOT analysis were derived from the provided business description and product pipeline information, focusing on areas of potential expansion and inherent industry characteristics.